# Array Biopharma, now a wholly owned trials: 25 (2026)

ClinicalTrials.gov lists 25 trials with Array Biopharma, now a wholly owned subsidiary of Pfizer as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Array Biopharma, now a wholly owned subsidiary of Pfizer: 25 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 10, 2014 | NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 2 | Withdrawn | Non-Small Cell Lung Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02109653) |
| January 31, 2014 | NCT02050815 | MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Terminated | Hepatic Impairment | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02050815) |
| February 28, 2013 | NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1/2 | Terminated | Uveal Melanoma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01801358) |
| July 25, 2012 | NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01649336) |
| March 16, 2012 | NCT01556568 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 2 | Withdrawn | Cardiomegaly | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01556568) |
| December 21, 2011 | NCT01496495 | A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Myelodysplastic Syndromes | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01496495) |
| November 10, 2011 | NCT01469130 | A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Solid Tumor | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01469130) |
| June 1, 2011 | NCT01363232 | Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Solid Tumors, Selected Solid Tumors | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01363232) |
| May 11, 2011 | NCT01352273 | MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Solid Tumors | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01352273) |
| May 9, 2011 | NCT01349725 | A Safety Study of ARRY-502 in Healthy Subjects | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01349725) |
| March 16, 2011 | NCT01316822 | A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Metastatic Cancer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01316822) |
| November 25, 2010 | NCT01248923 | A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Multiple Myeloma, Plasma Cell Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01248923) |
| August 14, 2009 | NCT00959127 | A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer, Metastatic Colorectal Cancer | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00959127) |
| August 6, 2009 | NCT00952198 | A Safety Study of ARRY-403 in Patients With Type 2 Diabetes | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Type 2 Diabetes | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00952198) |
| June 9, 2009 | NCT00916227 | A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Myelodysplastic Syndromes | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00916227) |
| February 2, 2009 | NCT00833326 | A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Cancer | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00833326) |
| January 23, 2009 | NCT00828165 | A Safety Study of ARRY-300 in Healthy Subjects | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00828165) |
| November 13, 2008 | NCT00790049 | A Safety Study of ARRY-371797 in Healthy Subjects | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00790049) |
| August 7, 2008 | NCT00729209 | A Study of ARRY-371797 in Patients With Rheumatoid Arthritis | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Rheumatoid Arthritis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00729209) |
| July 4, 2008 | NCT00710736 | A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00710736) |
| April 2, 2008 | NCT00650767 | A Study of ARRY-438162 in Patients With Rheumatoid Arthritis | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 2 | Completed | Rheumatoid Arthritis | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00650767) |
| March 18, 2008 | NCT00637702 | A Study of ARRY-334543 in Patients With Advanced Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00637702) |
| April 19, 2007 | NCT00462358 | A Study of ARRY-520 in Patients With Advanced Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Solid Tumors | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00462358) |
| January 19, 2006 | NCT00278902 | A Study of ARRY-334543 in Patients With Advanced Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Cancer | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00278902) |
| June 17, 2004 | NCT00085787 | A Study of ARRY-142886 in Patients With Advanced Cancer | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 | Completed | Advanced Cancer | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00085787) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Terminated | 2 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Myelodysplastic Syndromes | 2 |
| Arthritis, Rheumatoid | 2 |
| Diabetes Mellitus, Type 2 | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Cardiomegaly | 1 |
| Noonan Syndrome | 1 |
| Cardiomyopathy, Hypertrophic | 1 |
| Biliary Tract Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Colonic Neoplasms | 1 |
| Rectal Neoplasms | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Fallopian Tube Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Ovarian Neoplasms | 1 |
| Multiple Myeloma | 1 |
| Leukemia, Plasma Cell | 1 |
| Paraproteinemias | 1 |
| Plasmacytoma | 1 |
| Neoplasm Metastasis | 1 |
| Uveal Melanoma | 1 |
| Melanoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Machine shops in the United States](https://specstream.ai/data/businesses/machine-shops/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Printing equipment suppliers in the United States](https://specstream.ai/data/businesses/printing-equipment-suppliers/united-states)
- [Septic services in the United States](https://specstream.ai/data/businesses/septic-services/united-states)
- [Threads and yarns wholesalers in the United States](https://specstream.ai/data/businesses/threads-and-yarns-wholesalers/united-states)
- [Wind energy companies in the United States](https://specstream.ai/data/businesses/wind-energy-companies/united-states)
